The report forecasts the global pneumococcal vaccine market to grow at a CAGR of 13.69% during the period 2016-2020.
Commenting on the report, an analyst from the research team said: Emergence of protein-based combination pneumococcal vaccines will be a key trend for market growth. There is an increasing number of new pneumococcal protein-based vaccines, which are undergoing clinical trial evaluations.
These protein-based vaccines consist of serotype-independent subunit vaccines containing purified proteins and antigens that are expressed by recombinant bacteria. These vaccines will avoid the problems of serotype replacement by directly targeting proteins that are highly preserved among many pneumococcal serotypes.
According to the report, availability of global action plans for pneumonia vaccines will be a key driver for market growth. A consultation was held in Geneva in 2006, where WHO, in collaboration with vaccine manufacturers, public health organizations, academic experts, and funding agencies from developed and developing countries, developed the global action plan for pneumococcal vaccine. The plan was intended to combat the global shortage of pneumococcal vaccine.
It is a comprehensive strategy focused on increasing the use of the vaccine, and increasing its production capacity and R&D. WHO is working to promote the use of pneumonia vaccines by encouraging its member states to develop a policy for pneumonia vaccination.
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
- Beijing Minhai Biotechnology
- Eli Lilly
- Genocea Biosciences
- Nuron Biotech
- Panacea Biotec
- S K Chemicals
- Serum Institute of India
- Valneva Austria
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Pneumococcal vaccine: Overview
PART 06: Market landscape
PART 07: Geographical segmentation
PART 08: Market drivers
PART 09: Impact of drivers
PART 10: Market challenges
PART 11: Impact of drivers and challenges
PART 12: Market trends
PART 13: Vendor landscape
PART 14: Appendix
PART 15: About the Author
For more information about this report visit http://www.researchandmarkets.com/research/h2xxqb/global
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-pneumococcal-vaccine-market-cagr-growth-of-1369-by-2020---trends-technologies--opportunities-report-2016-2020---key-vendors-gsk-abera-baxter-300313281.html
SOURCE Research and Markets